Daniel K. Spiegelman

Co-Founder at Rapidscan Pharma Solutions, Inc.

Daniel K. Spiegelman

Daniel K. Spiegelman

Co-Founder at Rapidscan Pharma Solutions, Inc.

Overview
Career Highlights

BioMarin Pharmaceutical, Inc.
CV Therapeutics, Inc.
Filtini, Inc.

RelSci Relationships

3544

Number of Boards

14

Birthday

1959

Age

61

Relationships
RelSci Relationships are individuals Daniel K. Spiegelman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Chairman & Founder at Amygdala Neurosciences, Inc.

Relationship likelihood: Strong

Director at Prothena Biosciences, Inc.

Relationship likelihood: Strong

Founder at Rapidscan Pharma Solutions, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Relationship likelihood: Strong

Former Vice President-BioOncology at Genentech, Inc.

Relationship likelihood: Strong

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Executive Medical Director, Global Oncology at Clinipace, Inc.

Relationship likelihood: Strong

Chief Scientific Advisor at Clarus Ventures LLC

Relationship likelihood: Strong

Chief Financial Officer & Founder at Amygdala Neurosciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Paths to Daniel K. Spiegelman
Potential Connections via
Relationship Science
You
Daniel K. Spiegelman
Co-Founder at Rapidscan Pharma Solutions, Inc.
Education
B.A. in Economics

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

M.B.A.

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

Career History
Co-Founder
2009 - Current

Rapidscan Pharma Solutions, Inc. provides novel technologies for the diagnosis of disease. Its products include Regadenoson which acts as a stress agent used in the diagnosis and risk stratification of cardiovascular disease. The company was founded by Brent K. Blackburn, Daniel K. Spiegelman and Louis G. Lange in 2010 and is headquartered in Palo Alto, CA.

Executive Vice President & Chief Financial Officer
2012 - 2020

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Chief Executive Officer
2009 - 2012
Boards & Committees
Independent Director
2010 - 2014

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Director
2003 - 2006

Xcyte Therapies is a development stage biotech company that develops therapeutic products which enhances the body’s natural immune responses to treat cancer, infectious diseases, and other medical conditions associated with weakened immune systems. Xcyte Therapies is based in the United States and the company was founded in 1996.

Transactions
Details Hidden

BioMarin Pharmaceutical, Inc. issued USD Common Stock

Investments
Details Hidden

Rapidscan Pharma Solutions, Inc. provides novel technologies for the diagnosis of disease. Its products include Regadenoson which acts as a stress agent used in the diagnosis and risk stratification of cardiovascular disease. The company was founded by Brent K. Blackburn, Daniel K. Spiegelman and Louis G. Lange in 2010 and is headquartered in Palo Alto, CA.

Public Holdings
Restricted data only for RelSci Professional users.
Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Daniel K. Spiegelman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Daniel K. Spiegelman's profile does not indicate a business or promotional relationship of any kind between RelSci and Daniel K. Spiegelman.